Aptevo Therapeutics Inc (NASDAQ: APVO) is a clinical-stage biopharmaceutical company that discovers and develops bispecific immunotherapy candidates. The company has no approved commercial products as of its 10-K filed March 26, 2026, and generates no product revenue, relying instead on capital markets activity, including common stock issuances and warrant transactions, to fund operations. Aptevo's two clinical-stage candidates, mipletamig and ALG.APV-527, are built on its proprietary ADAPTIR bispecific protein platform and target oncology indications. ALG.APV-527, developed in collaboration with Alligator Bioscience, targets 4-1BB and 5T4 and showed stable disease in 59% of efficacy-evaluable patients in early clinical testing, including breast, colon, and prostate cancer patients, per the FY2025 10-K. The company carries an accumulated deficit and has reported net losses in both FY2024 and FY2025. Marvin L. White serves as President and Chief Executive Officer.

Revenue model

Aptevo has no approved products and generates no commercial product revenue. Operations are funded through equity issuances, including common stock offerings and warrant inducement transactions, as disclosed in the FY2025 10-K filed March 26, 2026.

Products and services

Two clinical-stage bispecific immunotherapy candidates as of the FY2025 10-K: mipletamig and ALG.APV-527, both built on the proprietary ADAPTIR bispecific protein platform. ALG.APV-527 targets 4-1BB and 5T4 and is being evaluated in oncology, including breast, colon, and prostate cancer. No approved or commercialized products.

Customers and end markets

No commercial customers. End market is oncology, with clinical trials enrolling patients with solid tumors including breast, colon, and prostate cancer. The filing does not disclose partnerships with commercial-stage customers or payers.

Value-chain role

Early-stage drug discoverer and clinical developer. Aptevo conducts internal research using the ADAPTIR platform and has entered into collaboration agreements, including with MorphoSys AG and Alligator Bioscience, for co-development of certain candidates. The company relies on CROs and external manufacturers for clinical execution.

Geographic exposure

Headquartered in the United States. Clinical trials are subject to both FDA and EU regulatory frameworks, including the EU Clinical Trials Regulation (CTR) and the Clinical Trials Information System (CTIS), indicating clinical activity or plans in the EU/EEA. Specific geographic trial locations are not detailed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: Theriva Biologics Inc Old Ayala, Inc bioAffinity Technologies Inc Cabaletta Bio Inc Vyant Bio, Inc. Bio Green Med Solution Inc YIELD10 BIOSCIENCE, INC. NexImmune, Inc. Sigilon Therapeutics, Inc.